Detalles de la búsqueda
1.
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.
BMC Health Serv Res
; 12: 38, 2012 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22336471
2.
The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac.
Clin Microbiol Infect
; 28(12): 1636-1643, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35798146
3.
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
Clin Infect Dis
; 49(4): 612-22, 2009 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19591597
4.
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
Clin Infect Dis
; 42(2): 273-80, 2006 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16355341
5.
CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
AIDS
; 18(18): 2381-9, 2004 Dec 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-15622314
6.
Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses.
Int J Infect Dis
; 14 Suppl 4: S79-92, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20846891
7.
Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.
J Antimicrob Chemother
; 57(3): 520-6, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16387747
8.
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study.
J Acquir Immune Defic Syndr
; 41(1): 23-30, 2006 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16340469
9.
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
J Infect Dis
; 194(1): 20-8, 2006 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16741878
10.
Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study.
J Acquir Immune Defic Syndr
; 34(2): 184-90, 2003 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14526207
Resultados
1 -
10
de 10
1
Próxima >
>>